Bipolar Depression Drug Reduced Symptoms in Phase 2 Trial
Adults using elunetirom as an add-on therapy saw improved mood scores in a new clinical study.
Updated on Sept. 21, 2026 in Mental Health
Live Poll
Do you trust that new pharmaceutical breakthroughs effectively improve long-term daily functioning for mental health patients?
Autobahn Therapeutics has released results from its Phase 2 AMPLIFY-BD trial showing that elunetirom reduced symptoms for adults with bipolar depression. This investigational treatment, which has received FDA Fast Track designation, was studied in 21 participants.
Why it matters
Managing bipolar depression remains a significant clinical challenge for the 7 million U.S. adults living with the condition, as existing treatments often have limited efficacy. This trial sought to determine if adding a new therapy to current regimens could better address persistent depressive symptoms.
In a Phase 2 trial of 21 adults, participants receiving 2.8 micrograms of daily oral elunetirom as an adjunctive therapy experienced a 16.8 point mean reduction in HAMD-17 scores by Week 6. These preliminary findings also reported a 75% response rate and a 50% remission rate.
The players
Autobahn Therapeutics
A biotechnology company focused on developing therapies for central nervous system disorders.
FDA
The federal agency responsible for regulating the safety and efficacy of pharmaceutical products in the United States.
The details
Elunetirom functions by targeting CNS thyroid hormone receptors to potentially enhance mitochondrial health and neuroplasticity in the brain. In this study, participants added the medication to their existing mood stabilizer or antipsychotic regimen to observe its adjunctive effects. Common treatment-related adverse events included dizziness, diarrhea, and decreased free thyroxine levels.
Timeline
September 15-19, 2026: Trial results were presented at Psych Congress 2026.
Week 2: Participants showed a 9.7 point mean reduction in HAMD-17 scores.
Week 4: Participants showed a 13.7 point mean reduction in HAMD-17 scores.
Week 6: The trial reached its primary endpoint with a 16.8 point mean reduction.
Health Landscape
The study sits within a growing effort to develop adjunctive therapies that move beyond traditional monotherapy for mood disorders. It specifically builds upon the clinical objective of addressing residual depressive symptoms in patients already stabilized on standard mood medications.
These findings are preliminary and represent early-stage research, meaning the treatment is not yet available for clinical use. Patients interested in how new clinical trials might impact future care options should discuss their current symptoms and treatment plans with their physician.
The takeaway
This study suggests that targeting specific thyroid hormone receptors may offer a new pathway for managing bipolar depression. Patients should continue their current prescribed treatment plans and talk to their doctor about new research developments worth monitoring.
Further reading
For more on evolving research in mood disorder management, see the latest updates in Mental Health.
Live Poll
Do you trust that new pharmaceutical breakthroughs effectively improve long-term daily functioning for mental health patients?
